<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121002">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01874171</url>
  </required_header>
  <id_info>
    <org_study_id>RMRCT0034</org_study_id>
    <secondary_id>2011-005165-21</secondary_id>
    <secondary_id>ISRCTN33522080</secondary_id>
    <nct_id>NCT01874171</nct_id>
  </id_info>
  <brief_title>Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC</brief_title>
  <acronym>De-ESCALaTE</acronym>
  <official_title>Determination of Epidermal Growth Factor Receptor-inhibitor (Cetuximab) Versus Standard Chemotherapy (Cisplatin) Early And Late Toxicity Events in Human Papillomavirus-positive Oropharyngeal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Warwick</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Warwick</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <authority>Ireland: Irish Medicines Board</authority>
    <authority>Ireland: Research Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oropharyngeal squamous cell carcinoma (OPSCC) incidence is increasing rapidly in the
      developed world. This has been attributed to a rise in Human Papillomavirus (HPV) infection.
      HPV+OPSCC is considered a distinct disease entity, affecting younger patients and has a good
      prognosis following treatment. Subsequently, patients can live with the considerable side
      effects for several decades.

      Radiotherapy and cetuximab (Epidermal Growth Factor Receptor-inhibitor) have demonstrated
      similar efficacy to 'platin' chemoradiotherapy (current standard treatment containing
      platinum-based compounds) in head and neck cancer, but is potentially less toxic.

      Results of this trial will be used to determine the optimum treatment of this debilitating
      cancer, with the primary aim of decreasing toxicity and improving quality of life for
      HPV+OPSCC patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Severe (acute and late) toxicity (Grade 3-5) caused by cetuximab and radiotherapy to that caused by cisplatin and radiotherapy.</measure>
    <time_frame>Up to two years after end of treatment.</time_frame>
    <description>Compare the severe (acute and late) toxicity (Grade 3-5), as assessed by CTCAE Version 4, caused by cetuximab and radiotherapy to that caused by cisplatin and radiotherapy in patients with HPV+OPSCC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall number of events of acute severe toxicity between treatment arms.</measure>
    <time_frame>Up to and including three months after end of treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall number of events of late severe toxicity between treatment arms.</measure>
    <time_frame>From three months up to two years after end of treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life outcomes assessed by EORTC QLQ C30 and HN35 between the two treatment arms.</measure>
    <time_frame>Baseline, end of treatment, and 3, 6, 12 &amp; 24 months after end of treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on swallowing of the two treatment arms (assessed by MDADI and by PEG or RIG utilisation rate at 1 and 2 years).</measure>
    <time_frame>Baseline, end of treatment, and 3, 6, 12 &amp; 24 months after end of treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness of the two treatment arms (assessed by EuroQoL-5D).</measure>
    <time_frame>Up to two years after end of treatment.</time_frame>
    <description>Questionnaires completed at the following time points: Baseline, end of treatment, and 3, 6, 12 &amp; 24 months after end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival and recurrence between the two arms.</measure>
    <time_frame>Up to two years after end of treatment.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">304</enrollment>
  <condition>Oropharyngeal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three doses of cisplatin 100mg/m2 given at days 1, 22 and 43 from start of radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial dose of 400mg/m2 one week before start of radiotherapy followed by seven weekly doses of 250 mg/m2 during radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <arm_group_label>Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <arm_group_label>Cetuximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Joint Committee on Cancer (AJCC) TNM Stage III-IVa (T3N0-T4N0, and
             T1N1-T4N3) oropharyngeal squamous cell carcinoma (SCC) tumours

          -  Clinical multidisciplinary team decision to treat with primary curative cisplatin
             chemoradiotherapy

          -  No previous treatment including surgery, except node biopsies or diagnostic
             tonsillectomy

          -  Medically fit (ECOG 0, 1 or 2)

          -  Adequate cardiovascular, haematological, renal and hepatic function

          -  Age &gt; 18 years

          -  Written informed consent given

          -  Using adequate contraception [male and female participants]. Must take contraceptive
             measures during, and for at least three months after treatment.

        Exclusion Criteria:

          -  Distant metastasis (i.e. AJCC TNM stage IVc disease)

          -  AJCC TNM Stage T1-2N0 disease

          -  Treated with primary radical surgery to the primary site (e.g. resection)

          -  Concurrent use of CYP3A4 inducers or inhibitors. [A standard course of dexamethasone
             or aprepitant for the prevention of cisplatin-induced nausea and vomiting is
             permitted]

          -  Serious cardiac illness or other medical conditions precluding the use of cisplatin
             or cetuximab [no history of clinically significant cardiac disease, serious
             arrhythmias, or significant conduction abnormalities; no uncontrolled seizure
             disorder; no active neurologic disease; no neuropathy greater than grade 1]

          -  Patients who have p16+ tumours who also have N2b, N2c or N3 nodal disease and whose
             lifetime smoking history is also more than 10 pack years (i.e. have both risk
             factors).

          -  Pregnant or lactating

          -  Previous treatment for any other cancer with cytotoxics, radiotherapy or anti-EGFR
             therapies

          -  Inadequate renal, haematological or liver functions [Absolute neutrophil count
             &lt;1,500/mm3; platelet count &lt;100,000/mm3; WBC &lt;3,000/mm3; haemoglobin &lt;9 g/dL.
             [Haemoglobin correction by transfusion permitted.] Bilirubin &gt; 1.5 times upper limit
             of normal (ULN); alkaline phosphatase &gt; 2.5 times ULN; AST and ALT &gt; 2.5 times ULN.
             Creatinine &gt; 1.5 mg/dL; Creatinine clearance &lt; 60 mL/min]

          -  Patients with clinically significant hearing impairment

          -  Life expectancy less than 3 months

          -  Other malignancy within the past 3 years except basal cell skin cancer or
             pre-invasive carcinoma of the cervix.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hisham Mehanna, PhD, BMedSc (hons), FRCS</last_name>
    <role>Study Chair</role>
    <affiliation>University of Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tessa Fulton-Lieuw, MSc</last_name>
    <phone>44-2476151722</phone>
    <email>deescalate@warwick.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joanne Grumett, BSc (Hons)</last_name>
    <phone>44-2476151082</phone>
    <email>Joanne.Grumett@warwick.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal United Hospital</name>
      <address>
        <city>Bath</city>
        <zip>BA1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emma De Winton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Cancer Centre</name>
      <address>
        <city>Bebington</city>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Husband</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bradford Royal Infirmary</name>
      <address>
        <city>Bradford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jim McCaul</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology &amp; Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hoda Al Booz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Velindre Hospital</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mererid Evans</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cheltenham General Hospital</name>
      <address>
        <city>Cheltenham</city>
        <zip>GL53 7AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Audrey Cook</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Coventry &amp; Warwickshire</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrew Chan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital Birmingham</name>
      <address>
        <city>Edgbaston</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrew Hartley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Devon &amp; Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Hwang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Surrey County Hospital</name>
      <address>
        <city>Guildford</city>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephen Whitaker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St James's Institute of Oncology</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mehmet Sen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Peel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kevin Harrington</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ruheena Mendes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eleanor Aynsley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bernadette Foran</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manor Hospital</name>
      <address>
        <city>Walsall</city>
        <zip>WS2 9PS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrew Hartley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.warwick.ac.uk/go/deescalate</url>
    <description>De-ESCALaTE study website</description>
  </link>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 7, 2014</lastchanged_date>
  <firstreceived_date>June 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Warwick</investigator_affiliation>
    <investigator_full_name>Prof. Janet Dunn</investigator_full_name>
    <investigator_title>Professor of Clinical Trials</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
